{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BIBF+1120&page=2", "query": { "intervention": "BIBF 1120", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BIBF+1120&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BIBF+1120&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T04:35:01.329Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07335562", "title": "A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Sclerosis" ], "interventions": [ { "name": "BMS-986353", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 92, "start_date": "2027-02-03", "completion_date": "2030-11-11", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07335562" }, { "nct_id": "NCT00730821", "title": "Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "BIBW 2992", "type": "DRUG" }, { "name": "BIBF 1120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2007-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-08-21", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00730821" }, { "nct_id": "NCT03513484", "title": "Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A", "Fibroblast Growth Factor Basic Form Measurement", "FLT3 Internal Tandem Duplication", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-11-14", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03513484" }, { "nct_id": "NCT04093024", "title": "A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Diseases, Interstitial" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 39, "start_date": "2019-12-03", "completion_date": "2022-05-24", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 9, "location_summary": "Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04093024" }, { "nct_id": "NCT04419506", "title": "A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "BI 1015550", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 147, "start_date": "2020-07-28", "completion_date": "2021-10-15", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 11, "location_summary": "Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chesterfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04419506" }, { "nct_id": "NCT02225405", "title": "Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage IB Non-Small Cell Lung Carcinoma AJCC v7", "Stage II Non-Small Cell Lung Cancer AJCC v7", "Stage IIA Non-Small Cell Lung Carcinoma AJCC v7", "Stage IIB Non-Small Cell Lung Carcinoma AJCC v7", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2015-04-03", "completion_date": "2024-05-06", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02225405" }, { "nct_id": "NCT02802345", "title": "Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sildenafil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 274, "start_date": "2016-06-30", "completion_date": "2018-04-13", "has_results": true, "last_update_posted_date": "2019-01-11", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Stamford, Connecticut • Jacksonville, Florida + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02802345" }, { "nct_id": "NCT00806819", "title": "Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Nintedanib (BIBF1120)", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "B12", "type": "DRUG" }, { "name": "dexamethasone (or corticosteroid equivalent)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 718, "start_date": "2008-12", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 40, "location_summary": "Downy, California • Fountain Valley, California • Fullerton, California + 37 more", "locations": [ { "city": "Downy", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Meriden", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806819" }, { "nct_id": "NCT02665143", "title": "A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Nintedanib and AML induction", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2016-07-21", "completion_date": "2021-03-30", "has_results": true, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Nashville, Tennessee", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02665143" }, { "nct_id": "NCT03820726", "title": "A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Diseases, Interstitial" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 435, "start_date": "2019-04-16", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-09-30T04:35:01.329Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03820726" } ] }